文献速递心境障碍

拉莫三嗪治疗边缘型人格障碍的临床与成本效果:随机安慰剂对照试验

The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial.
PubMed 文献 · Am J Psychiatry · 2018-04-06

多中心双盲安慰剂对照试验纳入276名边缘型人格障碍患者,随机接受拉莫三嗪(至400 mg/日)或安慰剂,52周时ZAN-BPD评分组间 adjusted difference in means=0.1(95% CI=-1.8, 2.0),无差异;次要结局及直接护理成本亦无差异,提示拉莫三嗪不具临床或成本效果。

要点

  • 拉莫三嗪与安慰剂在52周ZAN-BPD评分上无显著差异(adjusted difference in means=0.1, 95% CI=-1.8, 2.0)。
  • 次要结局(抑郁症状、故意自伤、社会功能、健康相关生活质量、资源使用与成本、副作用及不良事件)无差异。
  • 两组直接护理成本相似,拉莫三嗪不具成本效果。

核心结论

  • 拉莫三嗪治疗边缘型人格障碍在52周时未显示临床有效性或成本效果。

研究设计与样本

  • 多中心、双盲、安慰剂对照随机试验,2013年7月至2016年11月招募276名18岁及以上符合边缘型人格障碍诊断标准者。
  • 排除共病双相情感障碍或精神病、已使用心境稳定剂者及有妊娠风险女性;按1:1随机分配至安慰剂组或拉莫三嗪组(至400 mg/日)。

主要发现

  • 52周随访195人(70.6%);拉莫三嗪组49人(36%)、安慰剂组58人(42%)仍在服用研究药物。
  • 52周ZAN-BPD平均分:拉莫三嗪组11.3(SD=6.6),安慰剂组11.5(SD=7.7),adjusted difference in means=0.1(95% CI=-1.8, 2.0)。
  • 次要结局无差异证据,两组直接护理成本相似。

关键数值与推荐

  • 主要结局为52周时ZAN-BPD评分,组间adjusted difference in means=0.1(95% CI=-1.8, 2.0)。
  • 拉莫三嗪剂量至400 mg/日,安慰剂为惰性对照。

临床怎么用

  • 对于边缘型人格障碍患者,不应常规使用拉莫三嗪以期改善核心症状或降低医疗成本。

局限性

  • 52周时仅195人(70.6%)随访,且拉莫三嗪组36%、安慰剂组42%仍在服研究药物,脱落可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors examined whether lamotrigine is a clinically effective and cost-effective treatment for people with borderline personality disorder. METHOD: This was a multicenter, double-blind, placebo-controlled randomized trial. Between July 2013 and November 2016, the authors recruited 276 people age 18 or over who met diagnostic criteria for borderline personality disorder. Individuals with coexisting bipolar affective disorder or psychosis, those already taking a mood stabilizer, and women at risk of pregnancy were excluded. A web-based randomization service was used to allocate participants randomly in a 1:1 ratio to receive either an inert placebo or up to 400 mg/day of lamotrigine. The primary outcome measure was score on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) at 52 weeks. Secondary outcome measures included depressive symptoms, deliberate self-harm, social functioning, health-related quality of life, resource use and costs, side effects of treatment, and adverse events. RESULTS: A total of 195 (70.6%) participants were followed up at 52 weeks, at which point 49 (36%) of those in the lamotrigine group and 58 (42%) of those in the placebo group were taking study medication. The mean ZAN-BPD score was 11.3 (SD=6.6) among those in the lamotrigine group and 11.5 (SD=7.7) among those in the placebo group (adjusted difference in means=0.1, 95% CI=-1.8, 2.0). There was no evidence of any differences in secondary outcomes. Costs of direct care were similar in the two groups. CONCLUSIONS: The results suggest that treating people with borderline personality disorder with lamotrigine is not a clinically effective or cost-effective use of resources.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Crawford MJ, Sanatinia R, Barrett B, et al. The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial. Am J Psychiatry. 2018. PMID: 29621901. doi:10.1176/appi.ajp.2018.17091006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。